The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.
Patrick Y. Wen
Consultant or Advisory Role - Novartis
Research Funding - Novartis
W. K. Alfred Yung
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Ingo K. Mellinghoff
No relevant relationships to disclose
Shakti Ramkissoon
No relevant relationships to disclose
Brian Michael Alexander
No relevant relationships to disclose
Mikael L. Rinne
No relevant relationships to disclose
Howard Colman
No relevant relationships to disclose
Antonio Marcilio Padula Omuro
No relevant relationships to disclose
Lisa Marie DeAngelis
No relevant relationships to disclose
Mark R. Gilbert
Consultant or Advisory Role - Novartis
John Frederick De Groot
No relevant relationships to disclose
Timothy Francis Cloughesy
No relevant relationships to disclose
Andrew S. Chi
No relevant relationships to disclose
Eudocia Quant Lee
No relevant relationships to disclose
Lakshmi Nayak
No relevant relationships to disclose
Tracy Batchelor
No relevant relationships to disclose
Susan Marina Chang
No relevant relationships to disclose
Michael Prados
No relevant relationships to disclose
David A. Reardon
Consultant or Advisory Role - Novartis
Keith L. Ligon
No relevant relationships to disclose